Containing Solid Synthetic Polymers Patents (Class 424/497)
-
Patent number: 8932639Abstract: The present invention relates to topical compositions containing solid particles that are stabilized via encapsulation into a cross-linked silicone matrix. The stabilized particles possess an electrical potential sufficient to prevent the particles from penetrating into the skin. The particles can readily be used either alone or in combination with other skin care actives to form topical compositions with improved stability and performance.Type: GrantFiled: July 9, 2012Date of Patent: January 13, 2015Assignee: ELC Management LLCInventor: Wilson A. Lee
-
Patent number: 8927025Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.Type: GrantFiled: May 9, 2011Date of Patent: January 6, 2015Assignee: Cima Labs Inc.Inventor: Ehab Hamed
-
Patent number: 8927026Abstract: A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier.Type: GrantFiled: April 4, 2012Date of Patent: January 6, 2015Assignee: The Procter & Gamble CompanyInventors: Jiten Odhavji Dihora, Mark Anthony Brown
-
Patent number: 8927010Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.Type: GrantFiled: March 31, 2014Date of Patent: January 6, 2015Assignee: Ironshore Pharmaceuticals & Development, Inc.Inventors: David Lickrish, Feng Zhang
-
Publication number: 20140377353Abstract: The present invention concerns a pharmaceutical product to induce endogenous exacerbated release of gut hormones, pyy and glp1, with therapeutic effect on obesity and type 2 diabetes mellitus. In tablets form, suitable dosage forms such as pills capable of disintegration from a certain range of Ph or specific Ph range between 6.0 and 7.0, so that the undigested or partially hydrolyzed content is released in the distal jejunum and preferably in the ileum/proximal colon. And by contact with macro-nutrient molecules, or their hydrolyzed fragments, such cells suffer intense amplified stimulus and secrete the said hormones, released at rates that are therapeutics for obesity of any degree and also for type II diabetes; mimicking that produced and performed in bariatric and metabolic surgeries by a noninvasive method.Type: ApplicationFiled: June 24, 2013Publication date: December 25, 2014Inventor: GILBERTO BORGES DE BRITO
-
Publication number: 20140377332Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.Type: ApplicationFiled: November 21, 2013Publication date: December 25, 2014Inventors: Florian N. Ludwig, Stephen D. Pacetti, Syed F.A. Hossainy, Dariush Davalian
-
Publication number: 20140377365Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).Type: ApplicationFiled: June 18, 2014Publication date: December 25, 2014Inventors: Libo WU, Wiwik WATANABE
-
Patent number: 8916588Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.Type: GrantFiled: March 31, 2014Date of Patent: December 23, 2014Assignee: Ironshore Pharmaceuticals & Development, Inc.Inventors: David Lickrish, Feng Zhang
-
Publication number: 20140370112Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Syed M. Shah, Noreen Hassan
-
Publication number: 20140370113Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.Type: ApplicationFiled: February 12, 2013Publication date: December 18, 2014Applicant: Diurnal LimitedInventors: Hiep Huatan, Richard Ross, Martin Whitaker
-
Publication number: 20140363371Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.Type: ApplicationFiled: December 19, 2012Publication date: December 11, 2014Inventors: Juntao Luo, Kit Lam
-
Patent number: 8906410Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: GrantFiled: March 22, 2013Date of Patent: December 9, 2014Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Publication number: 20140356441Abstract: A method for producing core-shell type particles, including: ring-opening polymerizing a ring-opening polymerizable monomer in a first mixture containing the ring-opening polymerizable monomer, porous particles, and a compressive fluid; and injecting a second mixture containing a polymer obtained in the ring-opening polymerizing, the porous particles, and the compressive fluid to thereby granulate into the core-shell type particles.Type: ApplicationFiled: May 15, 2014Publication date: December 4, 2014Applicant: RICOH COMPANY, LTD.Inventors: Masaki Watanabe, Chiaki Tanaka, Taichi Nemoto
-
Publication number: 20140356440Abstract: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Applicant: Zx Pharma, LLCInventors: Syed M. Shah, Daniel Hassan, Fred Hassan
-
Patent number: 8895067Abstract: The composition for stimulating an immune response in a subject comprises methyl vinyl ether and maleic anhydride copolymer-based nanoparticles. Said nanoparticles may further contain an allergen or an antigen and/or an immunostimulating agent, which may be contained inside said nanoparticles and/or at least partially coating the surface of said nanoparticles, and optionally a cross-linking agent. The immune response stimulating composition is useful as an adjuvant in immunotherapy and vaccines.Type: GrantFiled: April 28, 2005Date of Patent: November 25, 2014Assignee: Universidad de NavarraInventors: Juan Manuel Irache Garreta, Carlos Gamazo De La Rasilla, Maria Luisa Sanz Larruga, Marta Ferrer Puga, Beatriz San Román Aberasturi, Hesham H. A. Salman, Sara Gómez Martinez, Javier Ochoa Rep{dot over (a)}raz
-
Patent number: 8895073Abstract: Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis.Type: GrantFiled: March 21, 2011Date of Patent: November 25, 2014Assignee: Georgia Tech Research CorporationInventors: Barbara D. Boyan, Robert E. Guldberg, Stephen J. Kennedy, David N. Ku, Zvi Schwartz
-
Publication number: 20140342005Abstract: A method for producing triblock copolymer-coated metallic nanoparticle seeds which increases the size and shape homogeneity of the triblock copolymer-coated metallic nanoparticle seeds. A quantity of triblock copolymer-coated metallic nanoparticle seeds. A method for producing triblock copolymer-coated metallic nanoparticles which increases the size and shape homo-geneity of the triblock copolymer-coated metallic nanoparticles. A quantity of triblock copolymer-coated metallic nanoparticles. A method for producing modified metallic nanoparticles which increases the size and shape homogeneity of the modified metallic nanoparticles. A quantity of modified metallic nanoparticles.Type: ApplicationFiled: February 28, 2013Publication date: November 20, 2014Applicant: LOMA LINDA UNIVERSITYInventors: Ralph S. Kurti, JR., Christopher C. Perry, Theodore Sabir
-
Patent number: 8889193Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.Type: GrantFiled: February 25, 2011Date of Patent: November 18, 2014Assignee: The Johns Hopkins UniversityInventors: Peter J. McDonnell, Yasin A. Khan, Samuel K. Lai, Renata T. Kashiwabuchi, Ashley Behrens, Justin S. Hanes
-
Patent number: 8889161Abstract: The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.Type: GrantFiled: April 27, 2010Date of Patent: November 18, 2014Assignee: Premier Dental Products CompanyInventors: Mark A. Latta, Stephen M. Gross, William A. Mchale
-
Patent number: 8889192Abstract: The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect.Type: GrantFiled: July 6, 2011Date of Patent: November 18, 2014Assignee: Chang Gung UniversityInventors: Mu-Yi Hua, Hung-Wei Yang, Cheng-Keng Chuang, See-Tong Pang, Hao-Li Liu, Rung-Ywan Tsai, Kun-Lung Chuang
-
Patent number: 8889185Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.Type: GrantFiled: November 13, 2013Date of Patent: November 18, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Publication number: 20140335182Abstract: The present invention relates to a process for preparing an aqueous polymer dispersion by free-radical emulsion polymerization of a monomer mixture which comprises N,N-diethylaminoethyl methacrylate, to the polymer dispersion obtainable by this process, and to the use thereof.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: Maximilian Angel, Karl Kolter, Hartwig Voß
-
Publication number: 20140328933Abstract: Nanoparticles comprising VIP and their use in treating, e.g. pulmonary hypertension. Such nanoparticles provide improved delivery of VIP and allow for acute treatment and optionally for sustained release of VIP in a patient.Type: ApplicationFiled: June 16, 2011Publication date: November 6, 2014Inventor: Shaker Mousa
-
Publication number: 20140328763Abstract: The present invention relates to nanoparticle compositions and treatment of cardiovascular disease using nanoparticles to target Class A and B scavenger receptors. This invention further relates to methods of detecting cells that express scavenger receptors, detecting atherosclerotic lesions, and targeting bioactive amphiphilic macromolecules to cells that express scavenger receptors.Type: ApplicationFiled: August 8, 2012Publication date: November 6, 2014Applicants: THE TRUSTEES OF PRINCETON UNIVERSITY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Adam W. York, Prabhas V. Moghe, Kathryn E. Uhrich, Robert Prud'homme
-
Patent number: 8877247Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.Type: GrantFiled: February 22, 2010Date of Patent: November 4, 2014Assignee: Alpharma Pharmaceuticals LLCInventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
-
Patent number: 8877250Abstract: The invention provides a hollow nano-particle comprising a crosslinked shell and a void core; and a preparation method thereof. The hollow nano-particle may be used in rubber composition, tire product, and pharmaceutical delivery system etc.Type: GrantFiled: December 20, 2006Date of Patent: November 4, 2014Assignee: Bridgestone CorporationInventors: Xiaorong Wang, Mindaugas Rackaitis, Pat Sadhukhan
-
Publication number: 20140322317Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Inventors: Christopher J. SPEIRS, Peter MOIR, Richard WILLIAMS, Michael CLARK
-
Patent number: 8871235Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: GrantFiled: October 24, 2012Date of Patent: October 28, 2014Assignee: Synergy Biomedical LLCInventor: Mark D. Borden
-
Publication number: 20140314864Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Jianjun Cheng, Omid C. Farokhzad, Robert S. Langer, Benjamin A. Teply, Stephen E. Zale
-
Publication number: 20140314672Abstract: Nanoparticle therapeutic agents, formulations that include the nanoparticle therapeutic agents, and methods for treating diseases treatable by the therapeutic agents.Type: ApplicationFiled: April 3, 2014Publication date: October 23, 2014Applicant: IGDRASOL, INC.Inventor: Vuong Trieu
-
Patent number: 8865221Abstract: Swellable and degradable microspheres are described. The microspheres are prepared by a process that is reliable and high yielding, and makes use of a low temperature azo initiator, a small molecule chlorinated solvent as the organic phase, and a heat treatment step, and is carried out in absence of a crosslinking agent. The microsphere preparation made using the process is particularly useful as a degradable embolic material.Type: GrantFiled: January 5, 2011Date of Patent: October 21, 2014Assignee: E I du Pont de Nemours and CompanyInventor: Garret D. Figuly
-
Patent number: 8865220Abstract: The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 ?m, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly(lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof.Type: GrantFiled: June 14, 2010Date of Patent: October 21, 2014Assignee: Kaohsiung Medical UniversityInventors: Mei-Ling Ho, Gwo-Jaw Wang, Je-Ken Chang, Yin-Chih Fu, Cherng-Chyi Tzeng, Eswaramoorthy Rajalakshmanan
-
Patent number: 8859288Abstract: Methods to produce pH-sensitive microparticles that have an active agent dispersed in a polymer matrix have certain advantages over microcapsules with an active agent encapsulated in an interior compartment/core inside of a polymer wall. The current invention relates to pH-sensitive microparticles that have a corrosion-detecting or corrosion-inhibiting active agent or active agents dispersed within a polymer matrix of the microparticles. The pH-sensitive microparticles can be used in various coating compositions on metal objects for corrosion detecting and/or inhibiting.Type: GrantFiled: July 5, 2012Date of Patent: October 14, 2014Assignee: The United States of America as Represented by the Administrator of the National Aeronautics and Space AdministrationInventors: Wenyan Li, Jerry W. Buhrow, Scott T. Jolley, Luz M. Calle
-
Publication number: 20140302121Abstract: A composition comprising a cannabinoid receptor binding agent contained in a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Applicant: Wet Inc.Inventor: Jonathan Bevier
-
Patent number: 8852624Abstract: A biomedical implant according to this invention comprises ceramic complex, which includes a surface-modified basic ceramic particles, which are basic ceramic particles modified their surface with first biodegradable polymers, and the second biodegradable polymers. The first and second biodegradable polymer are combined each other and form a stereo complex. The biomedical implant has a superior effect to suppress inflammation caused by degradation of biodegradable polymers with improving its mechanical property.Type: GrantFiled: October 2, 2012Date of Patent: October 7, 2014Assignee: Korea Institute of Science and TechnologyInventors: Dong Keun Han, Yoon Ki Joung, Jong Hee Kang, Ji Yeon Choi, Chang Hun Kum
-
Patent number: 8852626Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: March 20, 2012Date of Patent: October 7, 2014Assignees: Otonomy, Inc., The Regents of the University of CaliforniaInventors: Jay Lichter, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Andrew M. Trammel, Jeffrey P. Harris
-
Publication number: 20140294982Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.Type: ApplicationFiled: November 14, 2012Publication date: October 2, 2014Inventors: Barbara Freund, Jörg Heeren, Peter Nielsen, Antonella Carambia, Johannes Herkel, Oliver Bruns, Ansgar Lohse, Stefan Lüth, Horst Weller, Sunhild Salmen
-
Publication number: 20140294983Abstract: A nanoparticulate composition for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both, or to the surface of the nanoparticle; (ii) an active compound selected from the group of doxorubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, a metal ion, a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention.Type: ApplicationFiled: December 19, 2013Publication date: October 2, 2014Applicant: BBS NANOTECHNOLOGY LTD.Inventors: János BORBÉLY, Zsuzsanna CSIKÓS, Ildikó SCHRIFFERTNE DENYICSKA
-
Publication number: 20140294909Abstract: A layer-by-layer (LbL) system, which alternately ionically complexes anionic AuNPs to two unique cationic polymers (disulfide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.Type: ApplicationFiled: October 12, 2012Publication date: October 2, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jordan J. Green, Corey J. Bishop, Daniel Peng, Stephany Yi Tzeng
-
Patent number: 8846104Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.Type: GrantFiled: February 13, 2012Date of Patent: September 30, 2014Assignee: Alpharma Pharmaceuticals LLCInventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
-
Publication number: 20140287038Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
-
Publication number: 20140287053Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: Eupraxia Pharmaceuticals USA LLCInventors: James A. Helliwell, Amanda M. Malone, Thomas J. Smith, Marc M. Baum
-
Publication number: 20140271890Abstract: The present invention relates to a controlled-release pharmaceutical composition which, when administered in the evening, promotes rapid sleep onset and makes it easy to wake up in the morning in a refreshing way. The composition comprises: a first portion having sleep-inducing activity, which is able to be degraded and absorbed in vivo within 5 minutes to 1 hour after administration; and a second portion having cognition-enhancing activity, which is able to be released in vivo after 4 to 8 hours from the start of absorption of the first portion. The composition, when administered in the evening, promotes rapid sleep onset and makes it easy to wake up in the morning in a refreshing way.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventor: Thaer Ahmad
-
Publication number: 20140271857Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex.Type: ApplicationFiled: May 20, 2014Publication date: September 18, 2014Applicant: TRIS Pharma Inc.Inventors: Andrea Nelson, Quin-Zene Chen, Harsh Mehta, Yu-Hsing Tu
-
Publication number: 20140271840Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Publication number: 20140271894Abstract: A fluorescent porous silica particle for drug delivery includes a bridged silane fluorescent dye incorporated throughout the particle's matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R?O)3Si—R—Si(OR?)3, where R is a fluorescent organic bridging group, and where R? is a methyl or ethyl group) and a tetralkoxysilane (e.g., Si(OR?)4, where R? is a methyl or ethyl group) in the presence of a surfactant generates matrix-incorporated fluorescent porous silica particles of a predetermined size and shape. A capping layer is then bonded onto the surface of each particle and, subsequently, the surfactant within the pores of each particle is removed. The capping layer reversibly changes between closed and opened states responsive to a stimulus. A payload is then loaded within of the pores by applying the stimulus to open the capping layer. The payload is then entrapped within the pores by removing the stimulus to close the capping layer.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Dylan J. Boday, Jason T. Wertz
-
Publication number: 20140271898Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Applicant: Inspirion Delivery Technologies, LLCInventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
-
Publication number: 20140271896Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Purdue Pharma L.P.Inventors: Rama ABU SHMEIS, Sheetal Muley, Zhixin Zong
-
Publication number: 20140271897Abstract: This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Pathak Holding, LLCInventor: Chandrashekhar P. Pathak
-
Publication number: 20140271895Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.Type: ApplicationFiled: July 16, 2013Publication date: September 18, 2014Applicants: EDGE THERAPEUTICS, INC., Evonik CorporationInventors: R. Loch Macdonald, Cara R. Davis, Kevin Burton, Gary Winchester, Angela R. Stella